Retatrutide

CAS NO:2381089-83-2

Retatrutide is a novel dipeptidyl peptidase – 4 (DPP – 4) inhibitor antidiabetic drug. It can prevent the degradation of glucagon and glucose – dependent insulinotropic polypeptide (GIP) by DPP – 4 enzyme in the intestine and blood, prolong their activity, thereby promoting insulin secretion from pancreatic β cells and reducing glucagon secretion from pancreatic α cells.

  • Appearance: White Powder of Crystalline
  • Purity: 99%
  • Capacity: 50 KG Per Year
  • Process: Solid-Phase Synthesis
  • Mol. F. :C221H342N646O68
  • Mol. Wt.: 4731.33 g/mol
  • Documents: DMF + FDA EIR
Make A Quick Enquiry

Related products

GLP-1 API

Semaglutide

CAS NO:910463-68-2

Semaglutide is an anti-diabetic medication used to treat type 2 diabetes and manage chronic weight.

Show More
GLP-1 API

Tirzepatide

CAS NO:2023788-19-2

Tirzepatide is the first drug in a class of agents known as dual GLP-1 and GIP receptor agonists.

show More
GLP-1 API

Retatrutide

CAS NO:2381089-83-2

Retatrutide is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).

show More

CDMO services

CDMO service is one of strengths of GenoHope. GenoHope can provide one-stop CDMO service from R&D to commercial production, especially for advanced intermediates and new compounds with “special high quality ” and “cost saving” requirements.

show More